✦ LIBER ✦

Cost-effectiveness of ranibizumab for the treatment of neovascular age-related macular degeneration in germany: Model analysis from the perspective of germany's statutory health insurance system

✍ Scribed by Aljoscha S. Neubauer; Frank G. Holz; Stefan Sauer; Timo Wasmuth; Christoph Hirneiss; Anselm Kampik; Wolfgang Schrader

Book ID: 113544266
Publisher: Elsevier Science
Year: 2010
Tongue: English
Weight: 145 KB
Volume: 32
Category: Article
ISSN: 0149-2918
DOI: 10.1016/j.clinthera.2010.07.010

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PSS10 Cost- Effectiveness of Ranibizumab

PSS10 Cost- Effectiveness of Ranibizumab in Patients with Neovascular Wet Age-Related Macular Degeneration (Namd) at the Mexican Social Security System (Imss)

✍ Arreola-Ornelas, H.; Rosado-Buzzo, A.; García-Mollinedo, L.; Dorantes-Aguilar, J 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB

Effectiveness of intravitreal ranibizuma

Effectiveness of intravitreal ranibizumab for the treatment of neovascular age-related macular degeneration in a Canadian retina practice: a retrospective review

✍ Bandukwala, Taha; Muni, Rajeev H.; Schwartz, Carol; Eng, Kenneth T.; Kertes, Pet 📂 Article 📅 2010 🏛 Canadian Ophthalmological Society 🌐 English ⚖ 250 KB

PSS7 THE COST-EFFECTIVENESS OF RANIBIZUM

PSS7 THE COST-EFFECTIVENESS OF RANIBIZUMAB COMPARED TO PDT-VAND BSC FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION IN CANADA

✍ G Lozano-Ortega; RW Machuk; HE Hass; M Barbeau; MK Mathen 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 75 KB

Cost-Effectiveness Analysis of Ranibizum

Cost-Effectiveness Analysis of Ranibizumab versus Verteporfin Photodynamic Therapy, Pegaptanib Sodium, and Best Supportive Care for the Treatment of Age-Related Macular Degeneration in Greece

✍ Kostas Athanasakis; Vasilios Fragoulakis; Vasiliki Tsiantou; Panagiotis Masaouti 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 551 KB